Table I.
Patient characteristics and previous laboratory imaging results
| Characteristic | ABPA |
Non-ABPA |
P | ||||
|---|---|---|---|---|---|---|---|
| ABPA | No. | Af sIgE+ | No. | Af sIgE− | No. | ||
| Female sex, no. (%) | 24 (57.1) | 42 | 18 (51.4)† | 35 | 28 (73.7) | 38 | .12 |
| Age (years) | 62.2 (13.3) | 39 | 68.0 (13.4) | 35 | 65.9 (17.0) | 38 | .14 |
| Body mass index (kg/m2) | 21.7 (4.8) | 25 | 21.4 (3.7) | 29 | 22.7 (4.1) | 29 | .38 |
| Smoking history (%) | 42 | 33 | 37 | .39 | |||
| No | 83 | 73 | 78 | ||||
| Current | 12 | 27 | 19 | ||||
| Past | 5 | 0 | 3 | ||||
| Age (years) at diagnosis of asthma | 36.3 (23.6) | 38 | 35.3 (24.5) | 31 | 45.2 (23.2) | 37 | .15 |
| Period (years) from asthma diagnosis to airway lesion diagnosis | 18.5 (20.8) | 36 | 23.6 (24.1) | 28 | 12.4 (18.0) | 32 | .31 |
| Childhood pneumonia, no. (%) | 2 (5.4) | 37 | 2 (6.1) | 33 | 7 (20.0) | 35 | .08 |
| Previous laboratory and image data | |||||||
| Blood test | |||||||
| WBC (μL) | 8252 (3017) | 39 | 8511 (3226) | 35 | 7532 (2959) | 36 | .30 |
| Neutrophil (μL) | 4610 (1946) | 38 | 5812 (3387) | 32 | 5165 (3247) | 34 | .51 |
| Monocyte (μL) | 453 (213) | 38 | 439 (226)† | 34 | 329 (137)∗ | 36 | .006 |
| Eos (μL) | 1181 (1369) | 40 | 606 (524) | 33 | 409 (575)∗ | 34 | .0002 |
| Eos ≥300/μL (%) | 78 | 40 | 70† | 33 | 44∗ | 34 | .051‡ |
| Eos ≥500/μL (%) | 70 | 40 | 48 | 33 | 26∗ | 34 | .002‡ |
| Basophil (μL) | 60 (41) | 36 | 52 (57) | 33 | 37 (32)∗ | 33 | .04 |
| Total IgE (IU/mL) | 3068 (4575) | 40 | 1569 (3000)† | 30 | 357 (521)∗ | 31 | <.0001 |
| Aspergillus-specific IgE (UA/mL) | 18 (21) | 42 | 10 (15)∗† | 35 | 0.2 (0.1)∗ | 37 | <.0001 |
| Specific IgE against: | |||||||
| Alternaria (+), no. (%) | 19 (76.0) | 25 | 10 (38.5)∗† | 26 | 0∗ | 26 | <.0001 |
| Cat dander (+), no. (%) | 14 (56.0) | 25 | 3 (13.6)∗ | 22 | 1 (3.2)∗ | 31 | <.0001 |
| Dog dander (+), no. (%) | 14 (58.3) | 24 | 2 (10.0)∗ | 20 | 2 (7.7)∗ | 26 | <.0001 |
| Orchard grass (+), no. (%) | 8 (32.0) | 25 | 6 (26.1) | 23 | 5 (20.8) | 24 | .67 |
| Mugwort (+), no. (%) | 11 (47.8) | 23 | 4 (22.2) | 18 | 4 (14.8)∗ | 27 | .03 |
| Cedar (+), no. (%) | 18 (72.0) | 25 | 17 (65.4)† | 26 | 13 (38.2)∗ | 34 | .02 |
| House dust mite (+), no. (%) | 20 (76.9) | 26 | 16 (57.1)† | 28 | 9 (26.5)∗ | 34 | .0004 |
| FEV1/FVC (%) | 65.6 (12.8) | 28 | 66.0 (13.4) | 28 | 64.6 (11.8) | 25 | 1.00 |
| %FEV1 (%) | 66.1 (27.7) | 27 | 77.4 (22.4) | 27 | 74.2 (25.3) | 25 | .23 |
| Exhaled nitric oxide (ppb) | 61.9 (55.9) | 17 | 36.6 (23.4) | 27 | 64.5 (63.0) | 26 | .25 |
| Sputum culture, no. (%) | |||||||
| Aspergillus spp (+) | 7 (19.4) | 36 | 2 (6.5) | 31 | 0∗ | 33 | .02 |
| Fungus (+) | 8 (22.2) | 36 | 2 (6.5) | 31 | 0∗ | 33 | .007 |
| Pseudomonas aeruginosa (+) | 6 (17.1) | 35 | 6 (20.0) | 30 | 6 (19.4) | 31 | .95 |
| Gram-negative bacteria (+) | 10 (28.6) | 35 | 15 (50.0) | 30 | 15 (48.4) | 31 | .14 |
| Airway lesions | |||||||
| Modified Reiff score | 3.8 (4.2) | 41 | 2.5 (3.4) | 32 | 2.9 (3.3) | 35 | .30 |
| No. of bronchiolitis-affected lobes | 3.1 (2.1) | 40 | 2.9 (2.2) | 31 | 2.8 (2.3) | 34 | .81 |
| Mucus score | 7.0 (4.8) | 19 | 5.4 (6.0) | 8 | 5.9 (3.8) | 11 | .47 |
| Presence of exacerbations and bronchopneumonia in last 2 years, no. (%) | |||||||
| Requiring systemic corticosteroids | 18 (56.3) | 28 | 12 (42.9) | 28 | 10 (34.5) | 29 | .22 |
| Requiring antibiotics | 14 (45.2) | 31 | 14 (48.3) | 29 | 10 (33.3) | 30 | .47 |
| Bronchopneumonia | 12 (38.7) | 31 | 12 (41.4) | 29 | 9 (30.0) | 30 | .64 |
Data are shown as means (SDs) unless otherwise noted. P value demonstrates variance across 3 groups. (+) indicates positive result.
Eos, Eosinophils; FVC, forced vital capacity.
∗
P < .05 vs ABPA.
†
P < .05 vs Af sIgE− group.
‡
P < .05 by Cochran-Armitage test for trend.